Motixafortide shows efficacy as primary treatment for pancreatic cancer in phase 2 trial
Pancreas image | Image credit: © Лилия Захарчук – Stock.adobe.com Motixafortide, a CXC4 inhibitor, when combined with the PD-1 inhibitor cemiplimab and the standard of care (SoC) chemotherapy treatment gemcitabine and nab-paclitaxel (MCGN) Phase 2 Data from the CheMo4METPANC trial (NCT04543071) showed some positive results against (mPDAC). This data, presented as an abstract as part […]